MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 3,000 shares of the stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $4.01, for a total transaction of $12,030.00. Following the transaction, the director now directly owns 141,950 shares of the company's stock, valued at $569,219.50. This represents a 2.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
John Joseph Johnston also recently made the following trade(s):
- On Monday, October 28th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $3.72, for a total value of $11,160.00.
MaxCyte Price Performance
MaxCyte stock opened at $4.11 on Tuesday. MaxCyte, Inc. has a 1-year low of $3.16 and a 1-year high of $5.55. The stock's 50 day moving average price is $3.77 and its 200 day moving average price is $4.02. The company has a market cap of $434.39 million, a PE ratio of -12.09 and a beta of 1.37.
MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. The business had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same quarter last year, the firm posted ($0.11) EPS. On average, equities research analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.
Institutional Trading of MaxCyte
Man Who Called Nvidia Says: “Your Retirement Is Inside This Building.”
From Brownstone Research | Ad
In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents.
The company just became the world's third $3 trillion company...
And the stock is up massively since Jeff's recommendation.
Now, Jeff has found five under-the-radar stocks which could power your retirement.
A number of institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in shares of MaxCyte by 24.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 423,209 shares of the company's stock worth $1,659,000 after purchasing an additional 83,025 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in MaxCyte by 22.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company's stock worth $128,000 after buying an additional 5,927 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of MaxCyte by 15.3% in the second quarter. Rhumbline Advisers now owns 157,616 shares of the company's stock worth $618,000 after acquiring an additional 20,864 shares during the last quarter. American Century Companies Inc. lifted its position in shares of MaxCyte by 10.7% in the second quarter. American Century Companies Inc. now owns 144,110 shares of the company's stock valued at $565,000 after acquiring an additional 13,904 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of MaxCyte by 13.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company's stock valued at $3,961,000 after acquiring an additional 121,090 shares during the last quarter. 68.81% of the stock is currently owned by hedge funds and other institutional investors.
About MaxCyte
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
